Real-time Estimate
Cboe BZX
13:19:23 2024-06-26 EDT
|
5-day change
|
1st Jan Change
|
3.705
USD
|
-2.24%
|
|
+3.93%
|
-34.51%
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
949.7
|
368.3
|
282.8
|
231.7
|
-
|
-
|
Enterprise Value (EV)
1 |
603.6
|
105.5
|
50.43
|
110.2
|
60.35
|
-72.73
|
P/E ratio
|
-6.9
x
|
-3.31
x
|
-2.15
x
|
-1.79
x
|
-1.92
x
|
-1.92
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
34.1
x
|
36
x
|
13.1
x
|
EV / Revenue
|
-
|
-
|
-
|
16.2
x
|
9.39
x
|
-4.1
x
|
EV / EBITDA
|
-8.53
x
|
-0.97
x
|
-0.37
x
|
-0.77
x
|
-0.34
x
|
0.38
x
|
EV / FCF
|
-8.74
x
|
-1
x
|
-0.8
x
|
-0.89
x
|
-0.43
x
|
0.46
x
|
FCF Yield
|
-11.4%
|
-99.9%
|
-125%
|
-112%
|
-234%
|
219%
|
Price to Book
|
2.75
x
|
1.32
x
|
1.58
x
|
3.83
x
|
3.72
x
|
2.08
x
|
Nbr of stocks (in thousands)
|
46,506
|
48,399
|
50,062
|
61,140
|
-
|
-
|
Reference price
2 |
20.42
|
7.610
|
5.650
|
3.790
|
3.790
|
3.790
|
Announcement Date
|
22-03-29
|
23-03-16
|
24-03-14
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
6.803
|
6.429
|
17.73
|
EBITDA
1 |
-
|
-70.75
|
-108.6
|
-137.1
|
-142.8
|
-178.8
|
-190
|
EBIT
1 |
-
|
-72.88
|
-112.4
|
-143.3
|
-146.9
|
-165.5
|
-189.6
|
Operating Margin
|
-
|
-
|
-
|
-
|
-2,159.81%
|
-2,573.57%
|
-1,069.06%
|
Earnings before Tax (EBT)
1 |
-
|
-73.96
|
-108.5
|
-135
|
-138.5
|
-160.3
|
-184.8
|
Net income
1 |
-35.88
|
-73.96
|
-108.5
|
-135.4
|
-138.7
|
-160.4
|
-184.7
|
Net margin
|
-
|
-
|
-
|
-
|
-2,039.56%
|
-2,494.35%
|
-1,041.72%
|
EPS
2 |
-6.700
|
-2.960
|
-2.300
|
-2.630
|
-2.120
|
-1.979
|
-1.975
|
Free Cash Flow
1 |
-
|
-69.1
|
-105.4
|
-62.84
|
-123.6
|
-141
|
-159
|
FCF margin
|
-
|
-
|
-
|
-
|
-1,816.47%
|
-2,193.07%
|
-896.82%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
21-06-04
|
22-03-29
|
23-03-16
|
24-03-14
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
1.064
|
1.349
|
1.349
|
1.777
|
1.8
|
1.8
|
EBITDA
|
-
|
-
|
-
|
-
|
-31.42
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-23.39
|
-24.3
|
-27.23
|
-28.36
|
-32.49
|
-34.26
|
-37.22
|
-36.97
|
-34.86
|
-36.01
|
-36.25
|
-38.02
|
-37.59
|
-44.16
|
-46.26
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-3,384.49%
|
-2,687.41%
|
-2,818.53%
|
-2,114.94%
|
-2,453.43%
|
-2,569.96%
|
Earnings before Tax (EBT)
1 |
-23.4
|
-23.93
|
-26.47
|
-27.32
|
-30.78
|
-32.04
|
-34.99
|
-34.71
|
-33.27
|
-31.88
|
-34.3
|
-36.22
|
-36.21
|
-43.23
|
-45.41
|
Net income
1 |
-23.4
|
-23.93
|
-26.47
|
-27.32
|
-30.78
|
-32.04
|
-35.18
|
-34.88
|
-33.25
|
-31.97
|
-34.3
|
-36.22
|
-36.21
|
-43.23
|
-45.41
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-3,004.51%
|
-2,543.24%
|
-2,685.48%
|
-2,037.24%
|
-2,401.4%
|
-2,522.96%
|
EPS
2 |
-0.1100
|
-0.5100
|
-0.5700
|
-0.5800
|
-0.6300
|
-0.6500
|
-0.7100
|
-0.7000
|
-0.5800
|
-0.5300
|
-0.5461
|
-0.5522
|
-0.5184
|
-0.5433
|
-0.5100
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
22-03-29
|
22-05-11
|
22-08-11
|
22-11-10
|
23-03-16
|
23-05-11
|
23-08-10
|
23-11-09
|
24-03-14
|
24-05-09
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
346
|
263
|
232
|
122
|
171
|
304
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-69.1
|
-105
|
-62.8
|
-124
|
-141
|
-159
|
ROE (net income / shareholders' equity)
|
-
|
-49.5%
|
-35.1%
|
-60.1%
|
-60.9%
|
-135%
|
-75.5%
|
ROA (Net income/ Total Assets)
|
-
|
-35.6%
|
-30.6%
|
-41.9%
|
-42%
|
-33.6%
|
-29.1%
|
Assets
1 |
-
|
207.9
|
354.4
|
323.1
|
330.5
|
477.2
|
634.2
|
Book Value Per Share
2 |
-
|
7.430
|
5.750
|
3.570
|
0.9900
|
1.020
|
1.820
|
Cash Flow per Share
|
-
|
-
|
-1.960
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
9.73
|
12.9
|
19
|
12
|
8.97
|
9.37
|
Capex / Sales
|
-
|
-
|
-
|
-
|
176.4%
|
139.58%
|
52.86%
|
Announcement Date
|
21-06-04
|
22-03-29
|
23-03-16
|
24-03-14
|
-
|
-
|
-
|
Last Close Price
3.79
USD Average target price
15
USD Spread / Average Target +295.78% Consensus |
1st Jan change
|
Capi.
|
---|
| -34.51% | 232M | | +27.71% | 52.73B | | +37.49% | 39B | | -9.27% | 38.52B | | +28.85% | 30.38B | | -12.26% | 26.39B | | +11.76% | 26.08B | | +45.80% | 14.15B | | +32.92% | 12.6B | | -5.52% | 11.51B |
Other Biotechnology & Medical Research
|